Randox
Randox
Randox
The need for more extensive lipid profiling is on the increase, to truly
identify the risk of cardiovascular diseases, both in primary and secondary
risk categories; and as such provide the necessary tools to prevent and
reduce the risks. Randox offer a comprehensive cardiology product profile
which includes high performance reagents for the detection of conventional
risk factors, as well as emerging biomarkers associated with further risk.
LIPOPROTEIN SUBFRACTIONS
“BELOW THE AGE
OF 70, CVDs ARE
RESPONSIBLE FOR
39% OF ALL NCD “
DEATHS.
- World Heart Federation, 2017
VLDL
Density
LDL
HDL
Diameter
HDL CHOLESTEROL
Key Features of Randox HDL Cholesterol Clinical Significance
• UF Superior direct clearance methodology - ensuring truly High-density lipoproteins (HDL) are one of the major classes of plasma
accurate results even with abnormal samples lipoproteins. HDL is often referred to as ‘good cholesterol’ since it
• Liquid ready-to-use reagents - for convenience and ease of use transports cholesterol from the tissues to the liver for removal from the
• Extensive measuring range - of 0.189 - 3.73mmol/l for body. High levels of HDL can lower risk of developing heart disease.
measurement of clinically important results
• Applications available for an extensive range of biochemistry Performance in discrepant patient samples
analysers - which detail instrument-specific settings for the
convenient use of Randox HDL Cholesterol assays on a Fig.1 below compares the performance of the Randox direct
variety of systems clearance method and two other direct masking methods with the
ultracentrifugation reference method in two abnormal samples.
UF Benefits of the Randox Direct Clearance Method The Randox direct clearance method compares well with the
ultracentrifugation method; however the two other commercially
Although many direct methods of HDL measurement perform available direct masking methods seriously underestimate the
well with normal samples, they show reduced specificity and often concentration of HDL.
underestimate the concentration of HDL cholesterol in samples
containing abnormal lipoproteins e.g. samples from patients with
elevated triglycerides or liver damage. The Randox direct clearance
method offers superior performance to these methods and works
by completely removing all non-HDL components resulting in a high
degree of accuracy fugationand
Ultracentrifugation
Ultracentri specificity with abnormal samples
Ultracentrifugation
Direct Direct
method Direct
method method
Fig.1 Randox Direct Clearance Method vs Direct Masking Methods.1
2525 25 40 40 40
35 35 35 Ultracentrifugation
2020 20
30 30 30
25 25 25 Direct Method
1515 15
mg/dL
mg/dL
mg/dL
mg/dL
mg/dL
mg/dL
20 20 20
1010 10 15 15 15
10 10 10
55 5
5 5 5
00 0 0 0 0
RANDOXRANDOX
MethodRANDOX
1 Method Method
2 Method
1 RANDOX
Method
1 Method
Method
2 1 Method2 2 RANDOX
RANDOX
MethodMethod
1 Method
1 Method
2 2
SAMPLE 1SAMPLE
SAMPLE
1 SAMPLE
1 2 SAMPLE
SAMPLE
2 2
30
HDL
20
VLDL
10
Frac no.
“
THE DIAGRAM ABOVE
SHOWS HOW SPECIFIC
THE RANDOX DIRECT
CLEARANCE METHOD IS “
LDL CHOLESTEROL
Key Features of Randox LDL Cholesterol Excellent precision - Our LDL assay retains its precision even at
high levels of triglycerides.
Clinical Significance
UF Benefits of the Randox Direct Clearance Method
Fig.3 Mis-estimation of LDL by Calculation Method with Increasing Triglycerides TG>400 mg/dl
80 TG<400 mg/dl
100
% of samples misestimated by more than 10%
70
UC- Ultracentrifugation
60
50
40
50
30
20
10
0
0-50 51-100 101-150 151-200 201-300 301-400 401-600 601-800 0
Triglyceride concentration (mg/dl) UC RANDOX Friedewald
TG <400mg/dl TG >400mg/dl
This shows the mis-estimation of LDL cholesterol by the Friedewald equation with increasing triglycerides and how the Randox direct clearance method
UC = Ultracentrifugation
offers better performance.
VLDL
10
Randox LDL Cholesterol
Total Cholesterol
0
1 3 5 7 9 11 13 15 17 19 21 23 25 27
Frac No.
“
THE FRIEDEWALD
FORMULA HAS
BEEN REPORTED TO
MISCLASSIFY UP TO
50% OF PATIENTS2 “
Triglycerides: Cholesterol:
recommended recommended
levels below levels below
1.7 mmol/l 5.0 mmol/l
• Wide range of kits available - ensuring laboratories of all sizes • Wide range of kit sizes and formats available - offering choice
can find a product to suit their needs and minimal reagent waste
• Liquid ready-to-use reagents - for convenience and ease-of-use • Liquid and lyophilised formats available - for greater choice
• Standards included in manual kits - for user convenience (these • Standards included in manual kits - for user convenience (these
are for manual and semi-automated use only) are for manual and semi-automated use only)
• Extensive measuring range - of 0.865-16.6 mmol/l for • Extensive measuring range - of 0.134-12.7 mmol/l for
measurement of clinically important results measurement of clinically important results
• Applications available for an extensive range of biochemistry • Applications available for an extensive range of biochemistry
analysers - which detail instrument-specific settings for the analysers - which detail instrument-specific settings for the
convenient use of Randox Cholesterol assays on a variety of systems convenient use of Randox Triglyceride assays on a variety of systems
• CHOD-PAP method • GPO-PAP method
Total Cholesterol measures all lipoprotein sub-classes to assess a High triglyceride levels increase the atherogenicity of HDL and LDL
patient’s overall cholesterol level. High levels of cholesterol in the cholesterol. A triglyceride concentration of less than 1.7 mmol/l
blood are associated with atherosclerosis and an increased risk of is desirable. Levels higher than this are not only associated with
heart disease. As such Total Cholesterol testing plays a vital role in an increased risk of heart disease but also type 2 diabetes, kidney
preventative health care. Both the American National Cholesterol disease, hypothyroidism and pancreatitis.
Education Programme (NCEP) and the European Society of
Cardiologists (ESC) recommend levels below 5 mmol/l.
(sLDL) CHOLESTEROL
Key Features of Randox sLDL Cholesterol 100 y = 0.95x - 0.38
R = 0.910
Until recently, the primary methods of assessing a patient’s sLDL were
80
based on techniques such as ultracentrifugation and electrophoresis
sd LDL-C “SEIKEN“(mg/dl)
both of which are extremely laborious and time-consuming. 3 sLDL
can now be assessed in the routine biochemistry laboratory using the 60
Randox immunoturbidimetric assay.
TYPE 2 DIABETES
LOW HDL-C
“ Randox Lp(a)
•
UF The Randox Lp(a) assay is one of the only methodologies on
the market that detects the non-variable part of the Lp(a)
molecule and therefore suffers minimal size related bias -
providing more accurate and consistent results. The Randox
A FAMILY Lp(a) kit is standardised to the WHO/ IFCC reference material
HISTORY OF SRM 2B and is closest in terms of agreement to the ELISA
PREMATURE reference method.
CVD IS A RISK •
UF Five calibrators with accuracy-based assigned target values
are provided - which accurately reflect the heterogeneity of
FACTOR FOR
isoforms present in the general population
ELEVATED Lp(a)8 • Measuring units available in nmol/L upon request
• Highly sensitive and specific - method for Lp(a) detection in
serum and plasma
• Applications are available for a wide range of biochemistry
analysers - which detail instrument-specific settings for the
convenient use of Randox Lp(a) on a variety of systems
• Liquid ready-to-use reagents - for convenience and ease-of-use
Clinical Significance
Additional Risks
• Along with other tests, Lp(a) can provide additional information Repeat measurement is only necessary if treatment for high Lp(a)
on a patient’s risk factor of developing cardiovascular disease levels is initiated in order to evaluate therapeutic response.
• It is particularly useful for determining the risk of cardiovascular
disease (CVD) in specific populations due to ethnic variations EAS Consensus Panel
• The predictive value of Lp(a) is independent of LDL, non-HDL The evidence clearly supports Lp(a) as a priority for reducing
and the presence of other CVD risk factors cardiovascular risk, beyond that associated with LDL cholesterol.
• Lp(a) levels, like elevated LDL, is causally related to premature Clinicians should consider screening statin-treated patients with
development of atherosclerosis and CVD recurrent heart disease, in addition to those considered at
moderate to high risk of heart disease.
Guidelines for Clinical Significance
I. Premature CVD
II. Family hypercholesterolaemia
III. A family history of premature CVD and/or elevated Lp(a)
IV. Recurrent CVD despite statin treatment
V. ≥ 3% 10-year risk of fatal CVD according to the
European guidelines
VI. ≥ 10% 10-year risk of fatal and/or non-fatal CHD
according to the US guidelines
• Liquid ready-to-use reagents - for convenience and ease-of-use • Liquid ready-to-use reagents - for convenience and ease-of-use
• Wide measuring range - of 6.50-233 mg/dl for measurement • Wide measuring range - of 6.75-61.1 mg/dl for measurement
of clinically important results of clinically important results
• Limited interference - from Bilirubin, Haemoglobin, Intralipid® • Limited interference - from Bilirubin, Haemoglobin, Intralipid®
and Triglycerides, producing more accurate results and Triglycerides, producing more accurate results
• Applications available for an extensive range of biochemistry • Applications available for an extensive range of biochemistry
analysers - which detail instrument-specific settings for the analysers - which detail instrument specific settings for the
convenient use of Randox Apolipoprotein A-I assays on a convenient use of Randox Apolipoprotein A-II on a variety
variety of systems of systems
Apolipoprotein A-I is one of the main protein forms found in High Apolipoprotein A-II is a major constituent of High Density
Density Lipoproteins (HDL). The chief role of Apolipoprotein A-I Lipoprotein (HDL) particles and plays an important role in the
is in the activation of lecithin cholesterol acyl transferase (LCAT) processes of reverse cholesterol transport and lipid metabolism.
and the capture and removal of free cholesterol from extra Increased production of Apolipoprotein A-II promotes
hepatic tissues- this process is called reverse cholesterol transport. atherosclerosis by decreasing the proportion of anti-atherogenic
Apolipoprotein A-I may therefore be described as non-atherogenic, HDL containing Apolipoprotein A-I.
showing an inverse relationship to cardiovascular risk.
Clinical Significance
High decreased
NP HDL3 CHOLESTEROL HDL3-C = CVD risk
NEW!
What is HDL3 Cholesterol?
HDL comprises of several subclass particles, which differ in their sizes, In secondary prevention, increased risk for long-term hard clinical events is
densities and components. These HDL subclasses are considered to associated with low HDL3-C, but not HDL2-C or HDL-C, highlighting the
play different roles in the progression and regression of arteriosclerosis. potential value of subclassifying HDL-C.
HDL3-C is a smaller and more dense subfraction of the HDL particle.
3. Smaller, denser HDL3-C levels are primarily responsible for the
Standard tests for cholesterol, HDL, LDL and triglyceride levels only inverse association between HDL-C and incident CHD in this diverse
detect approximately 20% of all CAD patients. The other 80% can group of primary prevention subjects. (Joshi et. al, 2016)11
only be identified by differentiating subgroups, and carrying out more
detailed lipid testing. We aimed to clarify the associations of HDL-C subclasses with incident
CHD in two large primary prevention cohorts.
Clinical Significance
We measured cholesterol at baseline from the two major HDL subfractions
HDL is the scavenger of cholesterol within arterial walls and if HDL3 (HDL2 and HDL3) in 4114 African American participants from the Jackson
is in too low numbers the ability to remove this cholesterol is reduced. Heart Study and 818 predominantly Caucasian participants from the
Therefore it is widely accepted that there is an inverse correlation Framingham Offspring Cohort Study.
between HDL3-C and CVD risk, as demonstrated in a number of
recent key publications: Smaller, denser HDL3-C levels are primarily responsible for the inverse
association between HDL-C and incident CHD in this diverse group of
1. HDL3 subclass may be primarily responsible for the inverse primary prevention subjects.
association of HDL-C and CV disease. (Albers et. al, 2016)9
The aims of this secondary analysis were to examine the levels of Randox HDL3 Cholesterol
cholesterol in HDL subclasses (HDL2-C and HDL3-C), sdLDL-C, and
LDL-TG at baseline, as well as the relationship between these levels and CV • Liquid ready-to-use reagents - for convenience and ease-of-use
outcomes. Analyses were performed on 3094 study participants who were • Applications available for an extensive range of biochemistry
already on statin therapy prior to enrollment in the trial. analysers – which detail instrument-specific settings for the
convenient use of Randox HDL3-C on a variety of systems
The results of this secondary analysis of the AIM-HIGH Study indicate that • A 2 step procedure - based on patented technology from
levels of HDL3-C, but not other lipoprotein fractions, are predictive of CV Denka Seiken
events, suggesting that the HDL3 subclass may be primarily responsible for • Open vial stability of 28 days - when stored at +2 to +8°C
the inverse association of HDL-C and CV disease. • HDL3-C controls and calibrators available - offering the
complete testing package
2. In secondary prevention, increased risk for long-term hard • Measuring range of 4 - 60mg/dl - for the measurement of
clinical events is associated with low HDL3-C, but not HDL2-C or clinically important results
HDL-C, highlighting the potential value of subclassifying HDL-C. • Demonstrates a strong correlation with the conventional
(Martin et. al, 2015)10 Ultracentrifugation Method
• Allows for quantification of HDL2-C - by the subtraction of
We collaboratively analysed data from two, complementary prospective HDL3-C from total HDL-C
cohorts: the TRIUMPH study of 2465 AMI patients, and the IHCS study of • Measures total HDL3-C
2414 patients who underwent coronary angiography.
COMING
NP sPLA2-IIA SOON FROM • Individuals with sPLA2 levels in the highest quartile had a 58%
higher risk of cardiovascular death, MI or stroke, independent
RANDOX
of established risk factors12
What is sPLA2-IIA?
• sPLA2 activity but not LpPla2 activity was related to
atherosclerosis and increased risk of all-cause mortality in a
sPLA2 is a family of pro-inflammatory enzymes linked to the
sample of elderly subjects and predicted mortality or recurrent
formation and destabilization of atherosclerotic plaques. The
MI in a sample of post-MI patients13
sPLA2 protein expression increases with atherosclerotic lesions
• sPLA2 independently predicts death during a 16 week period
development. IIA is the dominant isoform within sPLA2 activity.
after acute coronary syndrome14
• Elevated concentrations of sPLA2–IIA mass and activity showed
Clinical Significance
a statistically significant increased risk for secondary CVD
events independent of a variety of potential confounders
sPLA2-IIA is a cardiovascular biomarker, which aids in prediction
including markers of inflammation, renal function, and
of coronary risk and in the prognosis of patients across different
haemodynamic stress, and even if considered simultaneously15
cardiac risk groups. It is a strong predictor of adverse outcomes,
including CVD, myocardial infarction, stroke and heart failure.
Randox sPLA2-IIA
Conclusions from key publications: • Liquid ready-to-use reagents – for convenience and
ease-of-use
• sPLA2 provides independent prognostic information beyond • Immunoturbidimetric method
established risk markers in patients with stable CAD12 • Complementary value-assigned controls and calibrators
• Strong association observed between increasing sPLA2 and risk available – offering a complete testing package
of heart failure, such that subjects in the highest quartile had • Applications available for an extensive range of biochemistry
nearly a 3-fold higher incidence of heart failure during follow up12 analysers – which detail instrument-specific settings for the
convenient use of Randox sPLA2-IIA on a variety of systems
Across 8 publications covering more than 13,200 patients, the significance of sPLA2 is
demonstrated within secondary and primary prevention:
Secondary prevention
sPLA₂ activity
3738 stable CHD patients PEACE study 12
2587 UA or AMI patients MIRACL study 14
1206 CHD patients KAROLA study 15
1036 Acute Coronary Events patients FAST-MI study 16,17
446 Acute CAD patients GRACE study 18
419 Emergency patients DIMU-Bichat study 19
Primary prevention
0 1 2 3 4 5
•
UF Two part, liquid ready-to-use reagent kit - for • Liquid ready-to-use reagents - for optimum convenience and
optimum convenience ease-of-use
UF Limited interference - from Bilirubin, Haemoglobin, Intralipid® • Latex Enhanced Immunoturbidimetric methodology -
and Triglycerides, producing more accurate results delivering high performance
• Calibrator is included in the kit - for greater convenience • Wide measuring range - of 0.477-10mg/l for measurement of
• Wide measuring range - of 1.7 - 47.9 μmol/L. The normal clinically important results
range for homocysteine is approximately 5-20μmol/L therefore • Limited interference - from Bilirubin, Haemoglobin, Intralipid®
the Randox assay can detect abnormal levels of homocysteine and Triglycerides, producing more accurate results
within a sample • Applications available for an extensive range of automated
• Excellent stability - of 28 days on-board the analyser at biochemistry analysers - which detail instrument-specific
+10°C, minimising reagent waste settings for the convenient use of Randox High Sensitivity CRP
• Applications available for an extensive range of automated assays on a variety of systems
biochemistry analysers - detailing instrument-specific settings
for the convenient use of Randox Homocysteine on a variety Clinical Significance
of systems
Risk Assessment - High Sensitivity CRP (hsCRP) in addition to
Clinical Significance lipid evaluation and risk scoring systems helps in the assessment
of cardiovascular disease (CVD) risk. Approximately half of all
Hyperhomocysteinemia, elevated levels of homocysteine, can be heart attacks occur in patients who have a normal lipid profile
associated with an increased risk of CVD. Patients with chronic and are classified as low risk based on traditional methods of
renal disease experience an excess morbidity and mortality due to risk estimation - the measurement of hsCRP can help clinicians to
arteriosclerotic CVD. Elevated concentration of homocysteine is a identify these individuals earlier. Healthy individuals with CRP levels
frequently observed finding in the blood of these patients. higher than 3mg/l are 2 to 4 times more likely to have a heart attack
or stroke. It can also be used to evaluate the risk of a recurrent
cardiac event.
Fig. 7 2006 AHA /
CDC Guidelines: Prognosis - In high risk groups there have been indications that CRP
hsCRP Levels vs
could be used as a prognostic tool.
Heart Attack Risk
NP ADIPONECTIN
Key Features of Randox Adiponectin Key references
• Automated assay - removes the inconvenience and time • Adiponectin levels are an independent predictor of CHD in
consumption associated with traditional ELISA based testing caucasian men initally free of CHD. Raising plasma adiponectin
• Liquid ready-to-use reagents - for convenience and level is highly protective of future CHD events in men22
ease-of-use • Low plasma adiponectin concentrations are associated with MI
• Latex Enhanced Immunoturbidimetric method - delivering in individuals below the age of 60, and this remains significant
high performance after adjustment for history of hypertension HDL cholesterol,
• Extensive measuring range - for measurement of clinically smoking and BMI23
important results • Low levels of adiponectin are associated with an increased
• Complementary controls and calibrators available - offering a risk of new-onset hypertension in men and postmenopausal
complete testing package women24
• Applications available for an extensive range of biochemistry • In children, serum levels of adiponectin are inversely related
analysers – which detail instrument-specific settings for the to hypertension. Low values of adiponectin in both obese and
convenient use of Randox Adiponectin on a variety of systems normal weight children are associated with a higher probability
of hypertension25
Clinical Significance
• The only CE-marked automated biochemistry assay available - • Heart-type Fatty Acid Binding Protein (H-FABP) is an unbound,
on the market for the routine assessment of Heart-type Fatty low molecular weight protein, located in the cytoplasm of
Acid Binding Protein cardiac myocytes.27
• Results are returned rapidly - typically within 14 minutes • The molecular weight is only 15kDa smaller than Myoglobin
• Liquid ready-to-use reagents - for convenience and ease-of-use (18kDa), Troponin I (22kDa), Troponin T (37kDa) and CK-MB
• Applications available for an extensive range of biochemistry (86kDa).
analysers - which detail instrument-specific settings for the • The function of H-FABP is in the intracellular uptake of long
convenient use of Randox H-FABP on a variety of systems chain fatty acids in the myocardium.
Ischemia Necrosis
Endothelial
Cell
Endothelial
Cell
• Elevated H-FABP is a significant predictor of death or MI up to • Using the combination approach consistently improved the
1 year.31 NPV, negative likelihood ratio, and the risk ratio.31
• H-FABP provides additional prognostic information, • Measurement of plasma h-FABP and hs-TropT together on
independent of Troponin T, ECG and clinical examination.28 admission appears to be more precise predictor of ACS rather
than either hs-Trop T or h-FABP alone. 32
H-FABP and Troponin - the optimum biomarker strategy
800
700
Concentration (µg/l)
Concentration (µg/l)
600
500
400
300
200
100
0
0 6 12 18 24 30 36 42 50
Time after symptom onset Times (Hours after onset of symptoms)
• H-FABP is highly specific to the heart – approximately 15-20 • Furthermore, the rapid return to baseline within 24 hours, offers
times more specific than Myoglobin.33 significant potential utility in patients with suspected reinfarction,
2h 24h 4d 14d
• The normal serum/plasma value is also much lower, compared instead of CK-MB.37
to Myoglobin.34
• Due to the low molecular weight & cytoplasmic location
of H-FABP, it is released extremely quickly after an ischemic
episode – detectable as early as 30 minutes afterwards.35,36
CK-MB MYOGLOBIN
Key Features of Randox CK-MB Key Features of Randox Myoglobin
• Wide range of kits sizes and formats available - offering • Latex Enhanced Immunoturbidimetric methodology - delivers
choice and minimal reagent waste high performance
• Liquid and lyophilised options available - to satisfy individual • Liquid ready-to-use reagents - for convenience and ease-of-use
user requirements • Wide measuring range of 20.1 - 725 ng/ml - with normal
• Randox Easy Fit reagents available - these reagents fit on to a levels of myoglobin being < 85 ng/ml
wide range of analysers, including Hitachi 717, Abbott Architect • Applications available for an extensive range of biochemistry
and Beckman Coulter AU Series machines; and are used in analysers - which detail instrument-specific settings for the
conjunction with validated analyser applications to ensure ease convenient use of Randox Myoglobin on a variety of systems
of programming
• Randox Easy Read reagents available for Hitachi analysers -
these reagents are packaged in dedicated bottles and are
barcoded for use, removing the need for any additional steps
to be completed
• Applications available for an extensive range of biochemistry
analysers - which detail instrument-specific settings for the
convenient use of Randox CK-MB on a variety of systems
DIGOXIN
Key Features of Randox Digoxin Clinical Significance
• Latex Enhanced Immunoturbidimetric methodology - delivers Digoxin is a drug commonly used to treat patients with heart failure
high performance and arrhythmias. It increases the strength of the heart’s contraction.
• Liquid ready-to-use reagents - for convenience and ease-of-use A stronger heartbeat means that the heart will circulate more blood
• Excellent stability - of 21 days on-board the analyser at +2 to and helps to reduce the symptoms of heart failure. Digoxin can also
+8°C, minimising reagent waste regulate, and slow the heart rate, and is therefore useful in certain
• Applications available - for an extensive range of heart rhythm disorders.
biochemistry analysers which detail instrument-specific
settings for the convenient use of Randox Digoxin on a As these conditions are generally chronic, monitoring Digoxin levels is
variety of systems useful in managing the patient’s condition.
up to
30%
of patients on low dose
aspirin therapy are
affected by aspirin
“resistance”
NP TxBCARDIOTM
Key Features of Randox TxBCardioTM Clinical Significance
• Highly accurate method for the evaluation of aspirin therapy Aspirin is the foundation of antiplatelet therapy and is widely prescribed in
effectiveness - the primary target of aspirin therapy is TxA2 the primary and secondary prevention of cardiovascular disease. However,
however this has a very short half-life making accurate not all patients receiving aspirin therapy respond in the same way with many
measurement difficult. When TxA2 degrades it is converted suffering from a lack of aspirin effect, also known as aspirin resistance.
into a number of metabolites, the most abundant of which
is 11dhTxB2. Randox TxBCardio™ specifically measures Clinical research has shown that patients who have a sub-optimum response
11dhTxB2 offering a highly accurate method for TxA2 to their aspirin therapy are over three times more likely to die from a
production analysis in patients heart attack or stroke than those who respond positively to such therapy.
• Automated latex-enhanced immunoturbidimetric assay - Up to 30% of patients on low dose aspirin therapy are affected by aspirin
facilitating aspirin therapy testing on automated biochemistry “resistance”.
analysers and eliminating the need for dedicated equipment
• Rapid analysis with an assay time of as little as ten minutes - The identification of these patients can be significantly improved through the
for more efficient results use of Randox TxBCardio™. Results generated by the Randox TxBCardio™
• Liquid ready-to-use reagents - for convenience and ease-of-use assay can be used to enable timely intervention by clinicians with patients
• Applications available for an extensive range of biochemistry deemed to be at increased risk. Patient management can then be altered
analysers - which detail instrument-specific settings for the via improved patient compliance, increased aspirin dosage levels and/or
convenient use of Randox TxBCardio™ on a variety of combination therapies with other drugs.
systems
Aspirin effect correlates to low urinary 11dhTxB2 Lack of Aspirin effect correlates to high urinary 11dhTxB2
TxB 2
TxB 2 TxB 2
TxB 2
Platelets Liver Platelets Liver
LOW HIGH
11dhTxB2 11dhTxB2 11dhTxB2
11dhTxB2
TxA2 TxA2
Urinary II-dehydro Urinary II-dehydro
thromboxane B2 thromboxane B2
Kidney Kidney
TxB2 TxB2
11dhTxB2 11dhTxB2
11dhTxB2 11dhTxB2
11dhTxB2
11dhTxB2
11dhTxB2
Urine Urine
Laboratory
REMOVABLE
STRIP OF
• CE - marked IVD product.
3 WELLS
• The array tests for 40 specific FH-causing mutations with
~78% coverage in the UK and Ireland, providing a targeted,
cost-effective assay for FH testing. Rapid turnaround time
allows results to be reported same day, compared to lengthy
SINGLE NGS screening which can take several weeks
UP TO 49
REACTION DISCRETE • The array consists of 2 mutation panels, allowing for single
WELL TEST REGIONS panel testing in cases of cascade screening of known mutations
for further laboratory cost savings
“
• Troponin I (cTnI)
BR3807
BR3807
Not all products are available for diagnostic use in USA. Please contact your local representative for further information.
Please note: All product performance information was achieved using the Randox RX series of clinical analysers. Results may vary depending on the analyser used.
REFERENCES 25
1. Izawa, S., Okada, M., Matsui, H. and Horita,Y. A new direct method for measuring HDL cholesterol which does not produce any biased values. Journal of Medical and Pharmaceutical Science. Vol. 37, p. 1385–1388 (1997).
2. Cohen et al (1997) Canadian Journal of Cardiology 13B No. 0762**
3. Hirano, T. Ito, Y. and Yoshino, G. Measurement of small dense low density lipoprotein particles. J Atherosclerosis Thromb. Vol. 12, no. 2, p. 67-72 (2005).
4. Austin, M.A., Breslow, J. L., Hennekens, C.H., Buring, J.E.,Willett,W. C. and Krauss, R.M. LDL subclass patterns and risk of MI. JAMA. Vol. 260, no. 13, p. 1917-21 (1988).
5. Teng Leary, E., Ph.D. AACC Presentation by Pacific Biometrics. AACC Annual Scientific Meeting & Clinical Lab Expo; 2006 Jul 23-27; Chicago, IL.
6. Marcovina, S.M. and Albers, J.J. Lipoprotein (a) measurements for clinical application. Lipid Res. Vol. 57, p. 526-37 (2016).
7. Kamstrup P.R.,Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA.Vol. 301, p. 2331-2339 (2009).
8. Nordestgaard, B. G., Chapman, M. J., Ray, K., Bore´n, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., Fisher, E., Kovanen, P.T., Kuivenhoven, J. A., Lesnik, P., Masana, L., Reiner, Z.,Taskinen, M. R.,Tokgo¨
zoglu, L., and Tybjærg-Hansen, A., for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal. Vol. 23, p. 2844-2853 (2010).
9. Albers, J. J., Slee, A., Fleg, J. L., O’Brien, K. D., Marcovina S. M. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Atherosclerosis.Vol. 251, p. 454 – 459, (2016).
10. Martin, S. S., Khokhar, A. A., May, H.T, Kulkarni, K. R., Blaha, M. J, Joshi, P. H.,Toth, P. P, Muhlestein, J. B., Anderson, J. L., Knight, S., Li,Y., Spertus, J. A., and Jones, S. R., on behalf of the Lipoprotein Investigators Collaborative (LIC). HDL
cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal.Vol. 36, p. 22–30 (2015).
11. Joshi, P. H.,Toth, P. P., Lirette, S.T., Griswold, M. E., Massaro, J. M., Martin, S. S, Blaha, M. J., Kulkarni, K. R., Khokhar, A. A., Correa, A., D’Agustino Sr, R. B., and Jones, S. R. on behalf of the Lipoprotein Investigators Collaborative (LIC) Study
Group. Association of high-density lipoprotein subclasses and incident coronary heart disease:The Jackson Heart and Framingham Offspring Cohort Studies. Eur J Prev Cardiol.Vol. 23, no. 1, p. 41 – 49 (2016).
12. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH,Toth PP, Muhlestein JB, Anderson JL, Knight S, Li Y, Spertus JA, Jones SR, Lipoprotein Investigators Collaborative (LIC). HDL cholesterol subclasses, myocardial
infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. European Heart Journal.Vol. 1, no. 36, p. 22-30 (2015).
13. O’Donoghue, M. L., Mallat, Z., Morrow, D. A., Benessiano, J., Sloan, S., Omland,T., Solomon, S. D., Braunwald, E.,Tedgui, A., and Sabatine, M. S. (2011). Prognostic Utility of Secretory Phospholipase A2 in Patients with Stable Coronary
Artery Disease. Clinical Chemistry. 57 (9), p. 1311-1317.
14. Lind, L., Simon,T., Johansson, L., Kotti, S., Hansen,T., Machecourt, J., Ninio, E.,Tedgui, A., Danchin, N., Ahlström, H. and Mallat, Z. (2012). Circulating Levels of Secretory- and Lipoprotein-Associated Phospholipase A2 Activities: Relation to
Atherosclerotic Plaques and Future All-Cause Mortality. European Heart Journal. 33 (23), p. 2946-2954.
15. Ryu, S. K., Mallat, Z., Benessiano, J.,Tedgui, A., Olsson, A. G., Bao, W., Schwartz, G. G. and Tsimikas, S. (2012). Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes.
Circulation. 125 (6), p. 757-766.
16. Koenig, W.,Vossen, C.Y., Mallat, Z., Brenner, H., Benessiano, J. and Rothenbacher, D. (2009). Association Between Type II Secretory Phospholipase A2 Plasma Concentrations and Activity and Cardiovascular Events in Patients with
Coronary Heart Disease. European Heart Journal. 30 (22), p. 2742-2748.
17. Simon T et al, European Society of Cardiology Meeting, 2008, P1317
18. Simon T et al, European Society of Cardiology Meeting, 2009, P5109
19. Mallat, Z., Steg, G., Benessiano, J.,Tanguy, M. L., Fox, K. A., Collet, J. P., Dabbous, O. H., Henry, P., Carruthers, K. F., Dauphin, A., Arguelles, C. S., Masliah, J., Hugel, B., Montalescot, G., Freyssinet, J. M., Asselain, B. and Tedgui, A. (2005).
Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes. J Am Coll Cardiol. 46(7):1249-1257.
20. Benessiano J et al, JE of the SFC Meeting, 2010, A0229-P256
21. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT,Tedgui A, Boekholdt SM. (2007). Circulating secretory phospholipase A2 activity and risk of incident coronary
events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol. 27(5), p. 1177-83.
22. Tsimikas, S., Mallat, Z., MD,Talmud, P. J., Kastelein, J. J. P., Wareham, N. J., Sandhu, M. S., Miller, E. R., Benessiano, J.,Tedgui, A., Witztum, J. L., Khaw, K.T. and Boekholdt, S. M. (2010). Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of
Fatal and Nonfatal Coronary Events. JACC. 56:12, p. 946-955.
23. Ai, M., Otokozawaw, S., Asztalos, B. F., White, C., Cupples, L. A., Nakajima, K., Lamon-Fava, S., Wilson, P. W., Matsuzawa,Y. and Schaefer, E. J. Adiponectin: an independent risk factor for coronary heart disease in men in the
Framingham Offspring Study. Atherosclerosis. Vol. 217, p. 543-548 (2011).
24. Persson, J., Lindberg, K., Gustafsson,T. P., Eriksson, P., Paulsson-Berne, G. and Lundman, P. Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. Journal of Internal Medicine. Vol. 268, no.
2, p. 194-205 (2010).
25. Jung, D. H., Kim, J.Y., Kim, J. K., Koh, S. B., Park, J. K. and Ahn, S.V. Relative contribution of obesity and serum adiponectin to the development of hypertension. Diabetes Res. Clin. Practise. Vol. 103, no. 1, p. 51-6 (2014).
26. Brambilla, P., Antolini, L., Street, M. E., Giussani, M., Galbiati, S.,Valsecchi, M. G., Stella, A., Zucotti, G.V., Bernasconi, S. and Genovesi, S. Adiponectin and hypertension in normal-weight and obese children. Am. J. Hypertens.Vol. 26, no. 2,
p. 257-64 (2013).
27. Menzaghi, C.,Trischitta,V. and Doria, A. Genetic Influences of Adiponectin on Insulin Resistance,Type 2 Diabetes, and Cardiovascular Disease. Perspectives in Diabetes, vol. 56, p. 1198-1209 (2007).
28. Glatz, J.F.C., van Bilsen, M., Paulussen, R.J.A.,Veerkamp, J., van der Vusse, G.J. and Reneman, R.S.. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or the calcium paradox. Biochim
Biophys Acta. Vol. 961, p. 148-52 (1988).
29. McCann, C.J., Glover, B.M., Menown, I.B., Moore, M.J., McEneny, J., Owens, C.G., Smith, B., Sharpe, P.C.,Young, I.S. and Adgey, J.A. Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain.
Am J Cardiol.Vol. 103, no. 1, p. 22-8 (2009).
30. McMahon, C.G., Lamont, J.V., Curtin, E., McConnell, R.I., Crockard, M., Kurth, M.J., Crean, P. and Fitzgerald, S.P. Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J
Emerg Med.Vol. 30, no. 2, p. 267-74 (2012).
31. Body, R., McDowell, G., Carley, S., Wibberley, C., Ferguson, J. and Mackway-Jones, K. A FABP-ulous ‘rule out’ strategy? Heart fatty acid binding protein and troponin for rapid exclusion of acute myocardial infarction. Resuscitation.
Vol. 82, no. 8, p. 1041-6 (2011).
32. McCann, C.J., Glover, B.M., Menown, I.B., Moore, M.J., McEneny, J., Owens, C.G., Smith, B., Sharpe, P.C.,Young, I.S. and Adgey, J.A. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T.
Eur Heart J.Vol. 29, no. 23, p. 2843-50 (2008).
33. Reddy, L.L., Shah, S.A., Dherai, A.J., Ponde, C.K. and Ashavaid,T.F.Troponin T and heart type fatty acid binding protein (h-Fabp) as biomarkers in patients presenting with chest pain. Indian J Clin Biochem.Vol. 31, no. 1, p. 87-92 (2016).
34. Data on file.
35. Ghani, F., Wu, A., Graff, L., Petry, C., Armstrong, G., Prigent, F. and Brown, M. Role of heart-type fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem. Vol. 46, p. 718-719 (2000).
36. Pelsers, M.M., Hermens, W.T. and Glatz, J.F. Fatty acid-binding proteins as plasma markers of tissue injury. Clin. Chem. Acta.Vol. 352, no. 1-2, p. 15-35 (2005).
37. Kleine, A.H., Glatz, J.F., van Nieuwenhoven, F.A. and van der Vasse, G.J. Release of heart type fatty acid binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem. Vol. 116, p. 155-162 (1992).
38. Data on file.
26
ACUSERA
Randox is a world leading manufacturer of multi-analyte, true third party controls.
Thousands of laboratories rely on us to accurately assess test system performance and
ultimately empower them with the confidence required to release patient test results.
With more than 390 analytes available across the Acusera range we can uniquely
reduce the number of individual controls required while simultaneously reducing
costs, time and storage space. A choice of formats are available, including liquid
or lyophilised, ensuring flexibility and suitability for laboratories of all sizes
and budgets. Some of our principle products include Clinical Chemistry,
Immunoassay, Urine, Immunology/Proteins, Cardiac Markers and Therapeutic
Drugs among others. As a primary manufacturer, Randox are also able
to offer the unique service of custom made controls.
RIQAS
Boasting over 45,000 participants and more than 360 parameters across
33 comprehensive & flexible EQA programmes, RIQAS is the largest
international EQA scheme. Designed to cover all areas of clinical testing, each
of our multi-analyte programmes benefit from a wide range of concentrations,
frequent reporting, rapid feedback and informative yet user-friendly reports.
Head Quarters
Randox Laboratories Ltd, 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom
+44 (0) 28 9442 2413 reagents@randox.com randox.com
International Offices
R E A G E N T S
Information correct at time of print. Randox Laboratories Ltd is a subsidiary of Randox Holdings Limited a company registered within Northern Ireland with company number N.I. 614690. VAT Registered Number: GB 151
6827 08. Product availability may vary from country to country. Please contact your local Randox representative for information. Products may be for Research Use Only and not for use in diagnostic procedures in the USA.